← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › ANTIMYCOTICS FOR SYSTEMIC USE › ANTIMYCOTICS FOR SYSTEMIC USE › Other antimycotics for systemic use
ibrexafungerp
J02AX07
Adult Dosing
- Vulvovaginal candidiasis: 300 mg (two 150 mg tablets) twice daily for 1 day (total dose: 600 mg)
- Reduction in risk of recurrent vulvovaginal candidiasis: 300 mg twice daily for 1 day, administered once a month for 6 months
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
Indications
- Treatment of vulvovaginal candidiasis (VVC)
- Reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC)
Mechanism of Action
- First-in-class triterpenoid antifungal agent (glucan synthase inhibitor)
- Inhibits 1,3-beta-D-glucan synthase, leading to disruption of fungal cell wall integrity
Contraindications
- Known hypersensitivity to ibrexafungerp
- Pregnancy (teratogenic effects observed in animal studies)
Adverse Reactions
- Diarrhea
- Nausea
- Abdominal pain
- Dizziness
- Vomiting
- Fatigue
Drug Interactions
- Strong CYP3A4 inhibitors (e.g., ketoconazole): significantly increase ibrexafungerp exposure; reduce ibrexafungerp dose
- Moderate CYP3A4 inhibitors: increase exposure; monitor for adverse reactions
- Strong or moderate CYP3A4 inducers: significantly decrease ibrexafungerp efficacy; avoid coadministration
- P-glycoprotein substrates: may increase concentrations of sensitive substrates
Curated Content: Needs Vetting Before Put to Clinical Use